21. January 2022 | Corporate News

Marinomed announces the appointment of Dr. Cornelia Kutzer as Chief Business Officer

Press release

Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, today announced that Dr. Cornelia Kutzer has been appointed as Chief Business Officer (CBO) of the company. As CBO, Dr. Kutzer will be responsible for further expanding Marinomed’s network of strategic partnerships both for product development and distribution in the therapeutic areas infectious diseases and immunology with an emphasis on ophthalmological indications.

“As we increase our efforts to realize the full potential of our product portfolio, we are delighted to now have such a successful and experienced management executive on board to optimize our business development activities,” Dr. Andreas Grassauer, CEO of Marinomed, said. “With her broad commercial expertise and impressive track record including high-value transactions, she will further advance Marinomed’s partnering strategy and will be an important part of our leadership team.”

Dr. Cornelia Kutzer, CBO of Marinomed, added: “It is a great opportunity to join Marinomed at this exciting stage of the company’s development. Marinomed is working on an interesting pipeline of new therapeutics to improve the treatment of a range of diseases. This also includes indications with a high unmet medical need, such as autoimmune gastritis. I am looking forward to my new role at Marinomed and to leveraging my experience to support Marinomed’s future strategic growth.”

The full press release is available as download here:

Marinomed announces the appointment of Dr. Cornelia Kutzer as Chief Business Officer
(167 KB)